Biotech

Monash IVF is Australia’s second biggest fertility clinics group with an estimated 25.3 per cent market share.

Opinion
IVF

The collateral damage from Monash IVF’s colossal embryo bungles

Monash IVF hasn’t just undermined its own reputation and customer confidence; it must result in a confidence wobble for the entire industry.

16 hours ago
Elizabeth Knight

Latest

Scientist Hugh Goold has completed the final stage of an international effort to create a synthetic yeast genome.

Science

Hugh once delivered cheese to the Queen. Now he’s built the key to synthetic life

The first-ever synthetic multicellular organism is ready to come to life after a Sydney breakthrough 10 years in the making.

April 5, 2025
Angus Dalton

CSL has seen lower vaccination rates in the US, which hit sales of its flu shots.

CSR Limited

Falling vaccination rates in Trump’s America hit Australian giant

CSL’s profits have taken a hit from Americans’ reluctance to get vaccinated, sending its shares downward.

February 11, 2025
David Swan

This week’s Bulls N’ Bears ASX Runner of the Week is… Bio-Gene Technology.

Sponsored
Bulls N' Bears

ASX Runners of the Week: Bio-Gene, Alterity, Aston & Canterbury

This week’s ASX Bulls N’ Bears Runner of the Week is… Bio-Gene Technology. The company’s shares leapt after revealing it scored a slice of two US defence grants.

January 31, 2025
Craig Nolan

Boston is an exception in the biotech world. While other centres struggle, the city’s biotechs are performing strongly.

Analysis
Mesoblast Limited

Riding the scariest rollercoaster on the ASX

If you thought crypto investors need to have strong stomachs, spare a thought for the investors who try their luck in the biotech sector.

December 26, 2024
William Bennett

This week’s Bulls N’ Bears ASX Runner of the Week is … Hydration Pharmaceuticals.

Sponsored
Bulls N' Bears

Hydration rehydrates share price with non-US asset sale

This week’s Bulls N’ Bears Runner of the Week is … Hydration Pharmaceuticals. The company sold its non-US assets for a sum five times its market capitalisation.

October 4, 2024
Craig Nolan

Novo Nordisk’s diabetes and weight-loss drugs, Ozempic and Wegovy, have soared to celebrity status.

Pharmaceuticals

It introduced Ozempic to the world. Now it must remake itself

Danish drugmaker Novo Nordisk has eclipsed French luxury group LVMH to become Europe’s most valuable company – thanks to demand for diabetes and weight-loss drugs.